ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

TOULOUSE, France--(BUSINESS WIRE)--Regulatory News:

ABIONYX Pharma (Paris:ABNX):

Market: Euronext Paris, Compartment C
ISIN code: FR0012616852

Date	Number of shares outstanding	Total voting rights
		Total gross ⁽¹⁾	Total net ⁽²⁾
December 31, 2025	35 511 655	45 189 888	44 971 283

(1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

(2) The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the recommendation made by the AMF on 17 July 2007.

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines in diseases where there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics through an extensive expertise in lipid science and a differentiated apoA-I -based technology platform. ABIONYX Pharma is committed to radically improving treatment outcomes in sepsis and critical care.

Contacts

ABIONYX Pharma
infos@abionyx.com

More News From ABIONYX Pharma

ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (FR0012616852 – ABNX – eligible for PEA-PME) (“Abionyx” or the “Company”), a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on its exclusive apoA-I technology platform, today announces the success of its capital increase with preferential subscription rights (the “Rights Issue”), launched on May 27, 2026, which has been subscribed at 100% after part...

ABIONYX Pharma : Combined Annual Shareholders’ Meeting on June 30, 2026: Availability of preparatory documents and procedures for participation and voting

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I technology platform, hereby notifies the public that the Company’s Combined Annual General Meeting will be held on Tuesday, June 30, 2026, at 4:00 p.m., at the Company’s registered office, 33-43 Av. Georges Pompidou, 31130 Balma, Fra...